Clinical trials: Castration Sensitive Prostate Cancer
- Condition Castration Sensitive Prostate Cancer
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Advanced Hormone Sensitive Prostate Cancer
Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate Cancer
Patients with prostate cancer and a history of cardiovascular disease treated with degarelix for their prostate cancer, will be followed for a period of one year.
- Trial name
- NCT02229253
- Testing
- degarelix
- Where
- Netherlands
- Volunteers
- 112 people
- Sponsor
- Ferring Pharmaceuticals